Compare BridgeBio Pharma Inc (BBIO) vs Dover Corp (DOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Dover Corp — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Dover Corp trades at $208.79 (market cap $28.30B). The key difference: Dover Corp is the larger of the two by market cap, and Dover Corp pays a 0.99% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | DOV | |
|---|---|---|
Market Cap | $16.61B | $28.30B |
Sector | Health | Industrials |
52-Week High | $90.17 | $233.31 |
52-Week Low | $47.29 | $161.16 |
Enterprise Value | $18.16B | $29.80B |
Dividend Yield | — | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Dover Corporation (DOV) trades at $211.13, up 0.14% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings beat expectations with EPS of $2.74, and the company raised its full-year guidance. A dividend increase to $0.525 per share and the acquisition of Cloeren highlight positive corporate actions. Valuation ratios include a P/E of 25.53 and net income margin of 13.48%, reflecting solid profitability.
The outlook for DOV is positive, driven by earnings momentum, raised guidance, and strategic acquisitions. Risks include exposure to manufacturing cycles and macroeconomic volatility. With 19 buy ratings and a consensus price target of $232.33, Wall Street sees upside potential, though investors should monitor execution on growth initiatives and sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →
